GSK plc Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2024-12-23: Form 6-K; Period of report 2024-12-23; Description DIRECTOR/PDMR SHAREHOLDING; Document a1582r.htm.
- 2024-12-20: Form 6-K; Period of report 2024-12-20; Description BLOCK LISTING APPLICATION; Document a8081q.htm.
- 2024-12-20: Form 6-K; Period of report 2024-12-20; Description HEADLINE RESULTS FROM PHASE III FIRST TRIAL; Document a8451q.htm.
- 2024-12-16: Form 6-K; Period of report 2024-12-16; Description JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION; Document a1958q.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2024-12-23 | 6-K | 2024-12-23 | DIRECTOR/PDMR SHAREHOLDING | a1582r.htm |
| 2024-12-20 | 6-K | 2024-12-20 | BLOCK LISTING APPLICATION | a8081q.htm |
| 2024-12-20 | 6-K | 2024-12-20 | HEADLINE RESULTS FROM PHASE III FIRST TRIAL | a8451q.htm |
| 2024-12-16 | 6-K | 2024-12-16 | JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION | a1958q.htm |
| 2024-12-16 | 6-K | 2024-12-16 | EMA GRANTS PRIME DESIGNATION FOR GSK 227 | a1116q.htm |
| 2024-12-16 | 6-K | 2024-12-16 | JEMPERLI RECEIVES POSITIVE CHMP OPINION | a1210q.htm |
| 2024-12-12 | 6-K | 2024-12-12 | DIRECTOR/PDMR SHAREHOLDING | a8992p.htm |
| 2024-12-09 | 6-K | 2024-12-09 | OVERALL SURVIVAL DATA PRESENTED FOR BLENREP | a2372p.htm |
| 2024-12-09 | 6-K | 2024-12-09 | BLENREP COMBINATION CHINA FILING ACCEPTANCE | a2364p.htm |
| 2024-12-09 | 6-K | 2024-12-09 | NUCALA COPD SUBMISSION ACCEPTED BY US FDA | a2715p.htm |
| 2024-12-05 | 6-K | 2024-12-05 | ZHIFEI CHINA COLLABORATION REVISED AND EXTENDED | a8828o.htm |
| 2024-12-02 | 6-K | 2024-12-02 | DIRECTOR/PDMR SHAREHOLDING | a4617o.htm |
| 2024-12-02 | 6-K | 2024-12-02 | TOTAL VOTING RIGHTS | a4573o.htm |
| 2024-11-27 | 6-K | 2024-11-27 | GSK LIQUID MENINGITIS VACCINE AUTHORISED IN EU | a7343n.htm |
| 2024-11-25 | 6-K | 2024-11-25 | BLENREP COMBINATIONS ACCEPTED FOR US FDA REVIEW | a4196n.htm |
| 2024-11-22 | 6-K | 2024-11-22 | JAPAN APPROVES FIRST RSV VACCINE FOR ADULTS 50-59 | a2598n.htm |
| 2024-11-19 | 6-K | 2024-11-19 | DIRECTOR/PDMR SHAREHOLDING | a8439m.htm |
| 2024-11-19 | 6-K | 2024-11-19 | GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT | a7692m.htm |
| 2024-11-14 | 6-K | 2024-11-14 | GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP | a1769m.htm |
| 2024-11-13 | 6-K | 2024-11-13 | BLOCK LISTING INTERIM REVIEW | a9631l.htm |
| 2024-11-12 | 6-K | 2024-11-12 | DIRECTOR/PDMR SHAREHOLDING | a9515l.htm |
| 2024-11-12 | 6-K | 2024-11-12 | GSK PUBLISHES PROVISIONAL 2025 DIVIDEND DATES | a7602l.htm |
| 2024-11-01 | 6-K | 2024-11-01 | TOTAL VOTING RIGHTS | a6559k.htm |
| 2024-10-30 | 6-K | 2024-10-30 | DIRECTOR/PDMR SHAREHOLDING | a2796k.htm |
| 2024-10-30 | 6-K | 2024-10-30 | 3RD QUARTER RESULTS | a1209k-originalv1edgarver.htm |
| 2024-10-24 | 6-K | 2024-10-24 | NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK | a3887j.htm |
| 2024-10-17 | 6-K | 2024-10-17 | DIRECTOR/PDMR SHAREHOLDING | a6194i.htm |
| 2024-10-16 | 6-K | 2024-10-16 | DIRECTOR/PDMR SHAREHOLDING | a4798i.htm |
| 2024-10-16 | 6-K | 2024-10-16 | FDA ACCEPTS NEW DRUG APPLICATION FOR GEPOTIDACIN | a2961i.htm |
| 2024-10-15 | 6-K | 2024-10-15 | DIRECTOR/PDMR SHAREHOLDING | a1010i.htm |
| 2024-10-15 | 6-K | 2024-10-15 | POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB | a9616h.htm |
| 2024-10-11 | 6-K | 2024-10-11 | DIRECTOR/PDMR SHAREHOLDING | a9370h.htm |
| 2024-10-10 | 6-K | 2024-10-10 | DIRECTOR/PDMR SHAREHOLDING | a7549h.htm |
| 2024-10-09 | 6-K | 2024-10-09 | ZANTAC (RANITIDINE) LITIGATION SETTLEMENTS | a6112h.htm |
| 2024-10-08 | 6-K | 2024-10-08 | POSITIVE EFFICACY DATA OF AREXVY OVER 3 SEASONS | a3654h.htm |
| 2024-10-01 | 6-K | 2024-10-01 | TOTAL VOTING RIGHTS | a5121g.htm |
| 2024-09-24 | 6-K | 2024-09-24 | DIRECTOR/PDMR SHAREHOLDING | a4837f.htm |
| 2024-09-24 | 6-K | 2024-09-24 | POSITIVE EU OPINION FOR GSK LIQUID MENVEO VACCINE | a2998f.htm |
| 2024-09-18 | 6-K | 2024-09-18 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | gskplc.htm |
| 2024-09-17 | 6-K | 2024-09-17 | JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA | a4081e.htm |
| 2024-09-13 | 6-K | 2024-09-13 | CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP | a0430e.htm |
| 2024-09-12 | 6-K | 2024-09-12 | DIRECTOR/PDMR SHAREHOLDING | a0053e.htm |
| 2024-09-12 | 6-K | 2024-09-12 | POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA | a8615d.htm |
| 2024-09-11 | 6-K | 2024-09-11 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | gsk6k.htm |
| 2024-09-11 | 6-K | 2024-09-11 | CHANGE OF REGISTERED OFFICE | a8152d.htm |
| 2024-09-11 | 6-K | 2024-09-11 | UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL | a6638d.htm |
| 2024-09-09 | 6-K | 2024-09-09 | DEPEMOKIMAB LATE-BREAKING DATA PRESENTED AT ERS | a4305d.htm |
| 2024-09-06 | 6-K | 2024-09-06 | DIRECTOR/PDMR SHAREHOLDING | a2930d.htm |
| 2024-09-06 | 6-K | 2024-09-06 | POSITIVE PHASE III RESULTS FOR NUCALA IN COPD | a1546d.htm |
| 2024-09-03 | 6-K | 2024-09-03 | TOTAL VOTING RIGHTS | a5689c.htm |
| 2024-08-29 | 6-K | 2024-08-29 | EMA APPROVAL ON AREXVY FOR 50-59 AT RISK | a0522c.htm |
| 2024-08-28 | 6-K | 2024-08-28 | NUCALA APPROVED IN JAPAN FOR USE IN CRSWNP | a9637b.htm |
| 2024-08-28 | 6-K | 2024-08-28 | SENKU DESIGNATION FOR BEPIROVIRSEN IN JAPAN | a8958b.htm |
| 2024-08-28 | 6-K | 2024-08-28 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | a8948b.htm |
| 2024-08-21 | 6-K | 2024-08-21 | DIRECTOR/PDMR SHAREHOLDING | a2783b.htm |
| 2024-08-20 | 6-K | 2024-08-20 | DIRECTOR/PDMR SHAREHOLDING | a9929a.htm |
| 2024-08-20 | 6-K | 2024-08-20 | B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION | a0178b.htm |
| 2024-08-16 | 6-K | 2024-08-16 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | a6776a.htm |
| 2024-08-12 | 6-K | 2024-08-12 | DIRECTOR/PDMR SHAREHOLDING | a1361a.htm |
| 2024-08-06 | 6-K | 2024-08-06 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | a2686z.htm |
| 2024-08-02 | 6-K | 2024-08-02 | FDA EXPANDS JEMPERLI APPROVAL | a8965y.htm |
| 2024-08-01 | 6-K | 2024-08-01 | TOTAL VOTING RIGHTS | a8347y.htm |
| 2024-07-31 | 6-K | 2024-07-31 | 2ND QUARTER RESULTS | a4712y.htm |
| 2024-07-29 | 6-K | 2024-07-29 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | a1789y.htm |
| 2024-07-29 | 6-K | 2024-07-29 | CHMP POSITIVE OPINION ON AREXVY FOR 50-59 AT RISK | a1391y.htm |
| 2024-07-19 | 6-K | 2024-07-19 | BLENREP EMA FILING ACCEPTANCE | a0215x.htm |
| 2024-07-18 | 6-K | 2024-07-18 | DIRECTOR/PDMR SHAREHOLDING | a9947w.htm |
| 2024-07-16 | 6-K | 2024-07-16 | DIRECTOR/PDMR SHAREHOLDING | a6380w.htm |
| 2024-07-15 | 6-K | 2024-07-15 | DIRECTOR/PDMR SHAREHOLDING | a4673w.htm |
| 2024-07-12 | 6-K | 2024-07-12 | DIRECTOR/PDMR SHAREHOLDING | a2297w.htm |
| 2024-07-03 | 6-K | 2024-07-03 | GSK AND CUREVAC COLLABORATION RESTRUCTURED | a8844u.htm |
| 2024-07-01 | 6-K | 2024-07-01 | TOTAL VOTING RIGHTS | a6501u.htm |
| 2024-06-28 | 6-K | 2024-06-28 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | gskplc.htm |
| 2024-06-24 | 6-K | 2024-06-24 | EMA VALIDATES JEMPERLI MARKETING AUTHORISATION | a4605t.htm |
| 2024-06-24 | 6-K | 2024-06-24 | OMJJARA APPROVED IN JAPAN FOR MYELOFIBROSIS | a4941t.htm |
| 2024-06-21 | 6-K | 2024-06-21 | DIRECTOR/PDMR SHAREHOLDING | a4579t.htm |
| 2024-06-12 | 6-K | 2024-06-12 | DIRECTOR/PDMR SHAREHOLDING | a1818s.htm |
| 2024-06-11 | 6-K | 2024-06-11 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | a8831r.htm |
| 2024-06-10 | 6-K | 2024-06-10 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | gskplc-8706r.htm |
| 2024-06-10 | 6-K | 2024-06-10 | FDA APPROVES AREXVY FOR ADULTS 50-59 AT RISK | a6411r.htm |
| 2024-06-03 | 6-K | 2024-06-03 | TOTAL VOTING RIGHTS | a8871q.htm |
| 2024-06-03 | 6-K | 2024-06-03 | UNPRECEDENTED RESULTS IN JEMPERLI TRIAL CONTINUE | a8879q.htm |
| 2024-06-03 | 6-K | 2024-06-03 | ASCO POSITIVE BLENREP DREAMM-8 TRIAL RESULTS | a7532q.htm |
| 2024-06-03 | 6-K | 2024-06-03 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | a7524q.htm |
| 2024-05-24 | 6-K | 2024-05-24 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | a7526p.htm |
| 2024-05-21 | 6-K | 2024-05-21 | POSITIVE PHASE III ASTHMA RESULTS FOR DEPEMOKIMAB | a1901p.htm |
| 2024-05-20 | 6-K | 2024-05-20 | DIRECTOR/PDMR SHAREHOLDING | gsk.htm |
| 2024-05-17 | 6-K | 2024-05-17 | CURRENT REPORT | gsk-6k_051624.htm |
| 2024-05-17 | 6-K | 2024-05-17 | GSK COMPLETES SALE OF SHARES IN HALEON PLC | a8223o.htm |
| 2024-05-14 | 6-K | 2024-05-14 | DIRECTOR/PDMR SHAREHOLDING | a4031o.htm |
| 2024-05-13 | 6-K | 2024-05-13 | BLOCK LISTING INTERIM REVIEW | a2101o.htm |
| 2024-05-08 | 6-K | 2024-05-08 | RESULT OF AGM | gsk.htm |
| 2024-05-08 | 6-K | 2024-05-08 | BOARD COMMITTEE CHANGE | a6791n.htm |
| 2024-05-03 | 6-K | 2024-05-03 | DIRECTOR/PDMR SHAREHOLDING | a2449n.htm |
| 2024-05-01 | 6-K | 2024-05-01 | 1ST QUARTER RESULTS | a6992m.htm |
| 2024-05-01 | 6-K | 2024-05-01 | TOTAL VOTING RIGHTS | a8670m.htm |
| 2024-04-24 | 6-K | 2024-04-24 | US FDA ACCEPTS NEW INDICATION FILING FOR JEMPERLI | a7742l.htm |
| 2024-04-19 | 6-K | 2024-04-19 | DIRECTOR/PDMR SHAREHOLDING | a2426l.htm |
| 2024-04-17 | 6-K | 2024-04-17 | DIRECTOR/PDMR SHAREHOLDING | a0190l.htm |
| 2024-04-17 | 6-K | 2024-04-17 | RESULTS FROM LONG-TERM DATA RELATING TO SHINGRIX | a8728k.htm |